Facebook Pixel High Growth Health Insurance Market Still Remains Underpenetrated | Bio Spectrum - Business - Les denne historien på Magzter.com

Prøve GULL - Gratis

High Growth Health Insurance Market Still Remains Underpenetrated

Bio Spectrum

|

February 2018 ,Vol 16 Issue 05

India’s healthcare industry is one of the fastest growing sectors and in the coming 10 years it is expected to reach $275 billion. Indian healthcare sector is much diversified and is full of opportunities in every segment which includes providers, payers and medical technology. With the increase in the competition, businesses are looking to explore for the latest dynamics and trends which will have positive impact on their business.

- Narayan Kulkarni

High Growth Health Insurance Market Still Remains Underpenetrated

Healthcare has become one of India’s largest sectors - both in terms of revenue and employment. Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services and increasing expenditure by public as well private players.

Indian healthcare delivery system is categorised into two major components - public and private. The Government, i.e. public healthcare system comprises limited secondary and tertiary care institutions in key cities and focuses on providing basic healthcare facilities in the form of primary healthcare centres (PHCs) in rural areas. The private sector provides majority of secondary, tertiary and quaternary care institutions with a major concentration in metros, tier I and tier II cities.

The healthcare sector in India is largely underpenetrated with government expenditure constituting approximately 1.4 per cent of India’s GDP. Private sector expenditure constitutes 70 per cent of the total healthcare expenditure out of which 62 per cent is out of pocket while only 8 per cent is covered through pre-financed instruments, as per World Bank Data (2014). Moreover, less than 30 per cent of India’s population has healthcare cover indicating considerable potential for the health insurance industry.

The health insurance industry, as of today, caters largely to institutional treatment, leading to considerable opportunities in targeting outpatient treatment in areas such as consultation fees, diagnostics and medicine expenses. The outpatient treatment, with medical inflation at ~15 per cent has created a strong need of developing a health savings account product combined with a robust health insurance plan in order to bring in spend efficiencies and protection for the Indian population.

FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum

Bio Spectrum

MAHE teams up with OpenAI to integrate AI to enhance outcomes

Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Jubilant Bhartia Foundation & McGill University to launch CoE in AI education

The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Heeding Auditory Warning Signs

By 2050, nearly 2.5 billion people are projected to have some degree of hearing loss, and more than 700 million might require hearing rehabilitation. That's according to the World Health Organization (WHO).

time to read

2 mins

April 2026

Bio Spectrum

Bio Spectrum

Botanic Healthcare on-boards Narahari Naidu as Group Chief Financial Officer

Secundarabad-based Botanic Healthcare, a globally leading nutraceutical company, has announced the appointment of Narahari Naidu as its Group Chief Financial Officer (CFO).

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Paras Health ropes in Balkishan Sharma as Group CHRO and Business Transformation Officer

Paras Health has announced the appointment of Balkishan Sharma as Group Chief Human Resources Officer (Group CHRO) and Business Transformation Officer.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Parse Biosciences unveils Evercode Whole Transcriptome V4 with shorter workflow

Parse Biosciences, a Qiagen company, has announced the launch of the new Evercode Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

UK deploys new bone scanners to help prevent fractures

Tens of thousands of patients at risk of osteoporosis and other bone conditions will get faster access to vital bone scans, as 20 new scanners are rolled out across England.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Cytiva expands Fast Trak process development and validation services facility in India

Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

ΑΙ TAKES INDIAN PHARMA REINS

The Indian pharmaceutical sector, one of the largest in the world, is undergoing a strategic transformation in the way it operates. As artificial intelligence (AI) gains prominence across the industry, companies are actively adopting Al-driven solutions to enhance efficiency across the entire pharmaceutical ecosystem. Organisations are investing in AI training programmes to keep their workforce future-ready, foster innovation, strengthen supply chains, and transition away from manual record-keeping. In this industry analysis, experts share their perspectives on how AI is shaping the future of the pharma sector.

time to read

10 mins

April 2026

Bio Spectrum

NIH halts arm of clinical trial evaluating potential stroke treatment

The National Institutes of Health (NIH) in the US has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) study, following a regular review by the Data Safety and Monitoring Board (DSMB).

time to read

1 min

April 2026

Translate

Share

-
+

Change font size